Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment

Elevated levels of alpha-fetoprotein (AFP) can be seen in patients with chronic hepatitis C (CHC) and liver cirrhosis without hepatocellular carcinoma and were negatively associated with treatment response. However, factors associated with its changes are not identified. We aimed in this study to ve...

Full description

Saved in:
Bibliographic Details
Published in:Arab journal of gastroenterology 2013-09, Vol.14 (3), p.94-98
Main Authors: El Raziky, Maissa, Attia, Dina, El akel, Wafaa, Shaker, Olfat, Khatab, Hany, Abdo, Shaimaa, Elsharkawy, Aisha, Esmat, Gamal
Format: Article
Language:English
Subjects:
Adult
Alpha-fetoprotein
alpha-Fetoproteins - metabolism
Antiviral Agents - therapeutic use
Body Mass Index
Chronic hepatitis C virus
Drug Therapy, Combination
Female
Hepatic fibrosis
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - pathology
Humans
Interferon-alpha - therapeutic use
Liver Cirrhosis - pathology
Male
Middle Aged
Polyethylene Glycols - therapeutic use
Predictive Value of Tests
Recombinant Proteins - therapeutic use
Ribavirin - therapeutic use
ROC Curve
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated levels of alpha-fetoprotein (AFP) can be seen in patients with chronic hepatitis C (CHC) and liver cirrhosis without hepatocellular carcinoma and were negatively associated with treatment response. However, factors associated with its changes are not identified. We aimed in this study to verify a cut-off value for AFP as a predictor of response to standard of care (SOC) antiviral therapy in Egyptian chronic hepatitis C virus (HCV)-infected patients and identify factors associated with its changes post treatment. A total of 175 chronic non-cirrhotic HCV-infected patients were evaluated for baseline serum AFP and liver biopsy were classified according to Ishak scoring system of hepatic fibrosis. All patients were scheduled to receive SOC antiviral therapy for 48weeks and had been followed up to week 72. Reassessment of AFP and repeated liver biopsy at week 72 were feasible only in 79 patients. High baseline AFP levels were observed in non-respondents (non-sustained virological respondents (non-SVRs)) (P
ISSN:1687-1979
2090-2387
DOI:10.1016/j.ajg.2013.08.005